glp-1 news employers Agonists: Managing Employee Health and Employer Costs GLP-1 Coverage in Employer Plans

When symptoms persist for more than a few weeks, medical evaluation for gastroparesis is essential and of utmost importance

They compared patients who initiated the glucagon-like peptide-1 receptor agonists (GLP-1s) semaglutide, tirzepatide, or liraglutide within one year of a cirrhosis diagnosis with those who underwent metabolic bariatric surgery (MBS) during the same period

Purpose-built for physicians GLP-1 use nearly doubled in 3 years among patients with MASH, compensated cirrhosis Key takeaways: GLP-1 use appears to be rising among patients with MASH and compensated cirrhosis

Side effects are typically mild and manageable

Short-acting ones (exenatide twice daily and lixisenatide) almost disappear from your blood between doses